Tell me more about this opportunity: Integration of drug sensitivity testing results (FOLFIRI/Oxaliplatin) into...

I appreciate your question, but I need to be transparent with you: I don't see specific information about FOLFIRI/Oxaliplatin drug sensitivity testing results in the documents you've uploaded.

Here's what I can see in your records:

What Your Documents Show About Drug Testing Plans:

From "Marlo's Treatment & Research Strategy - Working Document," I can see that comprehensive drug screening is planned through several services:

• TRACER (Seattle Children's) - Plans to screen against ~1,100 FDA-approved compounds
• First Ascent - Ex vivo drug sensitivity testing
• Certis Oncology - Patient-derived xenograft (PDX) models for in vivo drug testing
• SAGE Medic - Organoid development and drug screening

However, the actual results from these drug sensitivity tests don't appear to be in your uploaded documents yet — they seem to be planned next steps rather than completed results.

Important Questions for Your Team:

Since drug sensitivity testing is a key part of your strategy, I'd recommend asking your oncology team:

1. Which drug sensitivity testing platform will be used? (TRACER, First Ascent, or another service?)
2. Has tissue been collected and submitted for organoid/PDX development? If so, what's the timeline for results?
3. If FOLFIRI or Oxaliplatin testing is being considered, why these specific drugs? (Understanding the rationale helps you engage in treatment planning)
4. How will results be integrated into your treatment decisions? (Will they guide your next systemic therapy choice?)
5. What's the timeline for receiving results, and how will they be communicated to you?

Could you clarify: Are you asking about drug sensitivity testing that's already been done, or testing that's being planned? If you have additional documents with actual drug screening results, please share those and I can help interpret them.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.